CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Yi Lin, Sundar Jagannath(Mount Sinai Hospital), Enrique Zudaire(Centro de Investigación del Cáncer), Mounzer Agha(Dana-Farber Cancer Institute), Myo Htut(City Of Hope National Medical Center), Adam D. Cohen(Penn Center for AIDS Research), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Lida Bubuteishvili‐Pacaud, Nikhil C. Munshi(Dana-Farber Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Abhinav Deol(Wayne State University), Elizabeth O’Donnell(Harvard University), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Thomas Martin(University of California, San Francisco), Christopher delCorral, Carolyn C. Jackson(Centro de Investigación del Cáncer), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Deepu Madduri(Johnson & Johnson (United States))
Cited by 117
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k